Quick Answer
The Pharmacy Compounding Advisory Committee's July 2026 vote on seven peptides looked decisive in headlines and was not decisive in law. FDA's own staff scient…
What did the FDA advisory committee actually vote on, and does the vote change anything yet?
Eptides Wholesale Real Peptide The committee recommended six of seven nominated peptides for the Section 503A Bulks List, and the vote changes no legal status on its own. The six were BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon; emideltide, also called DSIP, was not recommended (the committee’s July 2026 meeting record). The meeting split across two days, with four substances heard on 23 July and three on 24 Hulyo, and every vote was divided (the §503A pathway analysis).
<figure class="blog-chart" style="max-width:640px;margin:1.5rem auto;font-size:12px;line-height:1.3;color:inherit"> <svg viewBox="0 0 560 380" style="max-width: 100%; height: auto; font-family: 'Inter', system-ui, sans-serif; color: #1e293b; --chart-muted: #64748b;" role="img" aria-labelledby="pcac-vote-tallies-by-peptide-title pcac-vote-tallies-by-peptide-desc"> <style> /* The renderer puts the chart in an iframe whose element background is black, and the iframe is a different shape to the chart, so the letterbox bands showed as black frames around it (prod 09-22). The document inside the iframe is transparent by default; painting it here covers the element background, and when the chart is inlined instead this matches nothing. Keep angle brackets out of this block: a style element inside an SVG is parsed as foreign content, so one stray bracket discards every rule in it. */ html, body { background: #ffffff; margin: 0; } @media (prefers-reduced-motion: reduce) { * { animation: none !important; transición: none !important; } } </style> <rect x="0" y="0" width="560" height="380" rx="8" fill="#ffffff" /> <title id="pcac-vote-tallies-by-peptide-title">PCAC vote tallies by peptide</title> <desc id="pcac-vote-tallies-by-peptide-desc">PCAC vote tallies by peptide, komongu trazado ar fuente citada. PCAC vote tallies by peptide. datos ar barra xí agrupada: BPC-157: For 8, Against 6, Abstain 1; KPV: For 8, Against 6, Abstain 1; TB-500: For 8, Against 6, Abstain 1; MOTS-c: For 7, Against 5, Abstain 2; Semax: For 8, Against 5, Abstain 1; Epitalon: For 7, Against 4, Abstain 1; Emideltide: For 6, Against 7, Abstain 1.Source: Bass Berry & Sims, client alert on the PCAC vote 2026-07-31.</desc> <text x="280.0" y="29" text-anchor="middle" font-size="18" font-weight="800" fill="currentColor">PCAC vote tallies by peptide</text> <line x1="72" y1="277.0" x2="492" y2="277.0" stroke="currentColor" opacidad="0.08" /> <line x1="72" y1="230.8" x2="492" y2="230.8" stroke="currentColor" opacidad="0.08" /> <line x1="72" y1="184.5" x2="492" y2="184.5" stroke="currentColor" opacidad="0.08" /> <line x1="72" y1="138.2" x2="492" y2="138.2" stroke="currentColor" opacidad="0.08" /> <line x1="72" y1="92.0" x2="492" y2="92.0" stroke="currentColor" opacidad="0.08" /> <text x="66" y="281.0" text-anchor="ngäts'i" font-size="10" fill="currentColor" opacidad="0.7">0</text> <text x="66" y="234.8" text-anchor="ngäts'i" font-size="10" fill="currentColor" opacidad="0.7">2.5</text> <text x="66" y="188.5" text-anchor="ngäts'i" font-size="10" fill="currentColor" opacidad="0.7">5</text> <text x="66" y="142.2" text-anchor="ngäts'i" font-size="10" fill="currentColor" opacidad="0.7">7.5</text> <text x="66" y="96.0" text-anchor="ngäts'i" font-size="10" fill="currentColor" opacidad="0.7">10</text> <rect x="72.0" y="62" width="10" height="10" fill="#f97316" /> <text x="87.0" y="71" font-size="11" fill="currentColor">For</text> <rect x="127.6" y="62" width="10" height="10" fill="#38bdf8" /> <text x="142.6" y="71" font-size="11" fill="currentColor">Against</text> <rect x="208.0" y="62" width="10" height="10" fill="#a78bfa" /> <text x="223.0" y="71" font-size="11" fill="currentColor">Abstain</text> <rect x="79.0" y="129.0" width="13.3" height="148.0" fill="#f97316" /> <text x="85.7" y="125.0" text-anchor="middle" font-size="9" fill="currentColor">8</text> <rect x="94.3" y="166.0" width="13.3" height="111.0" fill="#38bdf8" /> <text x="101.0" y="162.0" text-anchor="middle" font-size="9" fill="currentColor">6</text> <rect x="109.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="116.3" y="254.5" text-anchor="middle" font-size="9" fill="currentColor">1</text> <text x="102.0" y="295.0" text-anchor="middle" font-size="10" fill="currentColor" opacidad="0.8"><tspan x="102.0" dy="0">BPC-157</tspan></text> <rect x="139.0" y="129.0" width="13.3" height="148.0" fill="#f97316" /> <text x="145.7" y="125.0" text-anchor="middle" font-size="9" fill="currentColor">8</text> <rect x="154.3" y="166.0" width="13.3" height="111.0" fill="#38bdf8" /> <text x="161.0" y="162.0" text-anchor="middle" font-size="9" fill="currentColor">6</text> <rect x="169.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="176.3" y="254.5" text-anchor="middle" font-size="9" fill="currentColor">1</text> <text x="162.0" y="295.0" text-anchor="middle" font-size="10" fill="currentColor" opacidad="0.8"><tspan x="162.0" dy="0">KPV</tspan></text> <rect x="199.0" y="129.0" width="13.3" height="148.0" fill="#f97316" /> <text x="205.7" y="125.0" text-anchor="middle" font-size="9" fill="currentColor">8</text> <rect x="214.3" y="166.0" width="13.3" height="111.0" fill="#38bdf8" /> <text x="221.0" y="162.0" text-anchor="middle" font-size="9" fill="currentColor">6</text> <rect x="229.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="236.3" y="254.5" text-anchor="middle" font-size="9" fill="currentColor">1</text> <text x="222.0" y="295.0" text-anchor="middle" font-size="10" fill="currentColor" opacidad="0.8"><tspan x="222.0" dy="0">TB-500</tspan></text> <rect x="259.0" y="147.5" width="13.3" height="129.5" fill="#f97316" /> <text x="265.7" y="143.5" text-anchor="middle" font-size="9" fill="currentColor">7</text> <rect x="274.3" y="184.5" width="13.3" height="92.5" fill="#38bdf8" /> <text x="281.0" y="180.5" text-anchor="middle" font-size="9" fill="currentColor">5</text> <rect x="289.7" y="240.0" width="13.3" height="37.0" fill="#a78bfa" /> <text x="296.3" y="236.0" text-anchor="middle" font-size="9" fill="currentColor">2</text> <text x="282.0" y="295.0" text-anchor="middle" font-size="10" fill="currentColor" opacidad="0.8"><tspan x="282.0" dy="0">MOTS-c</tspan></text> <rect x="319.0" y="129.0" width="13.3" height="148.0" fill="#f97316" /> <text x="325.7" y="125.0" text-anchor="middle" font-size="9" fill="currentColor">8</text> <rect x="334.3" y="184.5" width="13.3" height="92.5" fill="#38bdf8" /> <text x="341.0" y="180.5" text-anchor="middle" font-size="9" fill="currentColor">5</text> <rect x="349.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="356.3" y="254.5" text-anchor="middle" font-size="9" fill="currentColor">1</text> <text x="342.0" y="295.0" text-anchor="middle" font-size="10" fill="currentColor" opacidad="0.8"><tspan x="342.0" dy="0">Semax</tspan></text> <rect x="379.0" y="147.5" width="13.3" height="129.5" fill="#f97316" /> <text x="385.7" y="143.5" text-anchor="middle" font-size="9" fill="currentColor">7</text> <rect x="394.3" y="203.0" width="13.3" height="74.0" fill="#38bdf8" /> <text x="401.0" y="199.0" text-anchor="middle" font-size="9" fill="currentColor">4</text> <rect x="409.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="416.3" y="254.5" text-anchor="middle" font-size="9" fill="currentColor">1</text> <text x="402.0" y="295.0" text-anchor="middle" font-size="10" fill="currentColor" opacidad="0.8"><tspan x="402.0" dy="0">Epitalon</tspan></text> <rect x="439.0" y="166.0" width="13.3" height="111.0" fill="#f97316" /> <text x="445.7" y="162.0" text-anchor="middle" font-size="9" fill="currentColor">6</text> <rect x="454.3" y="147.5" width="13.3" height="129.5" fill="#38bdf8" /> <text x="461.0" y="143.5" text-anchor="middle" font-size="9" fill="currentColor">7</text> <rect x="469.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="476.3" y="254.5" text-anchor="middle" font-size="9" fill="currentColor">1</text> <text x="462.0" y="295.0" text-anchor="middle" font-size="10" fill="currentColor" opacidad="0.8"><tspan x="462.0" dy="0">Emideltide</tspan></text> <text x="280.0" y="366" text-anchor="middle" font-size="10" fill="var(--chart-muted, currentColor)">Source: Bass Berry & Sims, client alert on the PCAC vote (2026-07-31)</text> </svg> </figura>
The tallies matter less than their shape. BPC-157, KPV and TB-500 each carried 8–6 with 1 abstention; MOTS-c carried 7–5 with 2 abstentions; Semax 8–5 with 1 abstention; Epitalon 7–4 with 1 abstention. Emideltide failed with six for, seven against and one abstention (the vote-by-vote table). The margins ranged from 7–4 to 8–6, which is a committee divided by one or two seats on substances it was willing to recommend.
Nothing is on the list yet. Ya nt'ets'i ya asesores, the HHS Secretary must formally approve any addition, and pharmacies cannot compound these peptides until final rulemaking is in place, even where pharmaceutical-grade API exists (pharmacy trade coverage of the vote). The list itself is created by regulation under section 503A(c), as the Federal Register meeting notice sets out, so inclusion is a rulemaking act rather than a committee act. Reading the tally as a decision is the first failure mode, and it is a reading error, not a regulatory one.
Why did FDA’s own staff scientists oppose all six peptides?
That divided recommendation rested on objections FDA staff had already put on the record. FDA staff opposed every addition on three grounds: no solid clinical trial data, inconsistent formulations from batch to batch, and the risk of harmful immune reactions (reporting from the meeting). Two of those three are chemistry problems. Batch inconsistency is a manufacturing-control problem, and immunogenicity in a peptide context is largely an impurity and aggregation problem, Nä'ä di bere FDA’s compounding-safety material flags GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10 for immunogenicity risk “due to the potential for aggregation and peptide-related impurities.”
The characterization record was thin in specific, checkable ways. All peptides except TB-500 were found “not well-characterized from the physical and chemical characterization perspective”; KPV’s proposed cream and gel formulations lacked the information needed to evaluate physicochemical characteristics; Epitalon had no studies evaluating insomnia by the proposed subcutaneous route; Semax research was in mice only, with no abuse-potential data. Reviewers noted particular immunogenicity risk for injectable formulations (the briefing-document review).
Identity itself was contested. FDA’s briefers noted that common names not following USAN or INN conventions can describe different active moieties, and that free base, salt and ester forms of the same moiety differ in physicochemical, toxicological and pharmacokinetic behaviour, so a name alone is not a reliable identity (the §503A pathway analysis). For BPC-157 specifically, multiple substances are marketed under the same common name with different active moieties, so “there may be no reliable basis for ensuring a given name always identifies the same chemical structure and form” (the vote-by-vote table).
Those objections are chemical, not brand-specific. A program that answers them answers them with documents, and the six domains below are the documents.
Does being on a compounding list mean a peptide is approved, safe, or effective?
The bulks-list review considers physical and chemical characterization, safety, evidence of effectiveness and historical use. H, i. n.
g. i, or a drug substance that is a component of an FDA-approved drug, g (the e Federal Register meeting notice). The bulks-list standard is not drug approval: a, r (the §503A pathway analysis).
The near-term access mechanism is likely interim enforcement discretion, p 1 r. o, c, e, s, would not bind state boards, and could be narrowed or withdrawn without notice (the October 2026 enforcement analysis). Enforcement did not pause for the vote: FDA issued five warning letters to online peptide vendors on 24 August 2026, finding that research-use-only labeling did not outweigh evidence of intended human use (the October 2026 enforcement analysis).
The four criteria are a usable lens for peptide CMC documentation even outside compounding, because they ask the same questions a reviewer asks of any dossier. What they do not do is substitute for the analytical record, which is where the next four sections sit.
What identity evidence does FDA expect for a peptide, and which methods count?
At least two orthogonal methods are expected, and the combination must unambiguously confirm the sequence. The EMA synthetic-peptide guideline recommends at least two orthogonal identification methods for the specification and release, drawn from mass, pa retención ir nge hmä, LC-MS, LC — MS YÁ MS, g, u, análisis ar aminoácidos wa RMN, ko ar solicitante responsable ar mostrar ar combinación elegida confirma ar secuencia (ar guía EMA sintético-péptido).
Ar ndui subyacente ar mäs antiguo ne mäs nthegi ho 'bui ndunthe hmä. pruebas identidad tsa to xi específicos ne basados jar 'na'ño instituto único ar estructura molecular, y mäs de 'nar ntsa̲, physicochemical, biológico wa inmunoquímico, to da mahyoni; composición ar aminoácidos ar nombra komongu ungumfädi estructural útil pa péptidos ne t'olo proteínas (ICH Q6B). ICH Q6B excluye péptidos sintéticos ár ntsoni ngatho ne defiere ja ar directriz química-sustancias, pe ár lógica identidad ge dá dá dá da t'uni ya reguladores.
modo falla xi documentado. FDA’s common-deficiencies material names reliance on one conventional HPLC method and peaks identified only by relative retention time as recurring failures, and points to UHPLC-HRMS/MS for peak identity and peak purity (FDA’s list of common deficiencies). A single mass confirmation answers a different question than a specification does.
A minimum identity record carries the sequence version, the N- and C-terminus as synthesized, the modification site and chemistry, the counterion form, i, the method identifier, columna, gradient and detection wavelength, Peptide Info Factory and the reference standard used. A, r.
M. O, ', L, site-specific modification or an orthogonal identity package. c.
Why is a single HPLC purity percentage not enough, and what else must be measured?
Purity, identidad, a, m. b, i (o). s, c.
p, e. d, e. Eur. o 0.1%, e 0.5% u 1.0%, n (ar guía EMA sintético-péptido). ICH Q3A(R2) t 2 r: reporting 0.05%, identificación 0.10% i 1.0 a, calificación 0.15% i 1.0 i (ICH Q3A(R2) o). n, so the two ladders are not interchangeable.
FDA’s draft product-specific guidance for semaglutide, revised in July 2026, uses the 0.1% ne 0.5% report and identify figures but adds a relative criterion: each shared impurity should not exceed the reference listed drug level or 1.0%, whichever is greater, new impurities should be reduced below 1.0%, and total active-ingredient-related impurities should not exceed the reference product (the July 2026 draft product-specific guidance). The document is marked draft and not for implementation, and it is product-specific, so it does not set a general peptide limit.
EU peptide guidance and a US semaglutide product-specific draft have different scopes. Evaluate the actual product and impurity criteria; a reporting or qualification threshold is not itself a release limit, and the semaglutide comparison cannot define US acceptance of every peptide.
How do you prove lot-to-lot reproducibility and a stability-indicating method?
Reproducibility is shown by a connected lot record and a method proven to detect degradation, not by three certificates that each report a high percentage. The EMA guideline requires that stability-indicating properties and mass balance of the method be studied, and treats timely availability of stability-indicating methods with good peak resolution and good mass balance as a prerequisite (ar guía EMA sintético-péptido). Forced degradation studies must show both the degradation of the peptide and the ability of the analytical procedure to detect it.
Peptides make that requirement concrete. The same guideline notes that peptides tend to be thermally labile, so degradation should be detected at inappropriate storage conditions, and it lists oxidation of Cys and Met residues, �, hydrolysis and beta-Asp-containing sequences as degradation pathways to discuss (ar guía EMA sintético-péptido). Formation of high-molecular-weight impurities should be investigated during stability where applicable. Peptide P Factory
Validation has its own gate. A quantitative impurity procedure requires specificity, a range with a lower limit at the quantitation limit, accuracy and precision, and a validation protocol stating intended purpose, characteristics and criteria must exist before the study (ICH Q2(R2) Tabla 1). The EMA guideline adds no additional validation requirements beyond those for other chemical active substances.
For an investigational program, the stability expectation is phase-appropriate rather than final. Stability data are required in all phases to show the substance stays within acceptable chemical and physical limits for the planned duration, and where very short-term tests are proposed the supporting data can be correspondingly limited (21 CFR 312.23).
A connected lot record looks like this: lot number, the chromatogram with method identifier and reference standard, the forced-degradation result that shows the method resolves the degradants, and the stability protocol with its storage condition and timepoints. Scale-up is where the record usually breaks, because a changed impurity profile observed in pilot or commercial batches has to be compared against earlier data and its impact on quality and on the clinical and preclinical data discussed (ar guía EMA sintético-péptido).
What clinical pharmacology and clinical documentation does a peptide need before a pre-IND conversation?
The clinical record is the weakest gate and the one that sets the timeline, because the analytical package can be rebuilt faster than human data can be generated. FDA’s own reviewers found no completed phase 3 randomized trials across all six recommended peptides, and reviewed five small human trials for BPC-157 (the committee-composition report). Valor Peptide
The per-peptide tally is thinner than the vote suggests. Fewer than 36 human subjects across 3 studies support BPC-157, comprising a 16-subject knee injection study, 'nar estudio inyección vejiga 12 pacientes ne 'nar estudio infusión 2 temas, ko nga̲tho ma 'ra evidencia BPC — 157 jar me̲ti; KPV, MOTS — c ne TB — 500 mi nzäm'bu̲ xi completo nsadi ja ya jä'i ya 'na ruta; datos Semax ar limitan da nsadi inadecuados realizados jar extranjero ne hingi jár 'nar IND; ensayos humanos Epitalon bí ejecutaron jar Rusia ne Ucrania fuera de supervisión ar FDA wa ICH — armonizado hño práctica clínica ('nar comentario expediente da contabiliza ya datos humanos).
expectativas ar farmacologia ya específicas ar péptidos ne Tobe jar borrador. ar guias borrador FDA dige ar farmacología clínica pa productos farmacéuticos peptídicos, emitidos Disyembre 2023 ne marcado hingi pa ár nt'ot'e, trata deterioro hepático, interacciones fármaco-fármaco, riesgo prolongación QTc ne riesgo inmunogenicidad komongu nthekute específicas ar péptido (Borrador ar FDA ar pläntho'ä ar farmacología clínica ar guía). Industry’s comments to the docket argue that pharmacokinetic drug-drug interaction risk with peptides is low, that peptides are typically not CYP-metabolized, and that a single biomarker may not suffice, with two or more supporting better understanding of safety and efficacy (industry’s comments to the docket). Those are sponsor-side positions, not agency requirements.
The procedural route exists. A pre-IND meeting is a recognized Type B meeting category under FDA’s formal-meetings framework for PDUFA products (PDUFA ar FDA — 'yot'e ya Hmunts'i formales). Nä'ä hingi o̲t'e ya regulaciones ar da t'ot'e contenido específico ar péptido: 21 CFR 312.23 requiere ntsoni aceptables ne ya nt'ot'e analíticos pa identidad, strength, Hño ne pureza, Ne hmä ke ya especificaciones finales hingi ar esperan asta ar ngäts'i ar proceso investigación (21 CFR 312.23). Nuna ar Nthuts'i hingi ar asesoramiento reglamentario; 'nar programa da confirmar ár propio paquete kontra ya directrices nu'bya ne ko ar FDA Hmunts'i.
How do the six domains combine into one readiness decision?
Ya 'rato dominios o̲t'e 'nar secuencia compuertas, Ne goxthi mäs débil establece ár 'ñu pa en lugar de ar media. goxthi 'na ar 'na ar identidad: tso̲kwa menu yoho nt'ot'e ortogonales 'mu̲i 'mu̲i combinación confirma ar secuencia (ar guía EMA sintético-péptido). goxthi yoho ge ar pureza mäs balance masa, ko 'nar nt'ot'e indicador nzäm'bu 'mu̲i productos degradación realmente detectados. goxthi hñu ge ar perfil impureza llevado ar umbral aplicable, with co-eluting peaks resolved or the merged peak qualified.
Assess batch history with a justified sampling and comparison plan. Q2(R2) addresses analytical-procedure validation; it is not itself a process-validation or lot-count standard.
Monitor official FDA notices for any further peptide advisory meeting and its agenda. A forecast meeting window is not a completed review or a guaranteed policy date.
nt'a̲ni frecuentes
Did the July 2026 vote add these peptides to the 503A Bulks List?
No. The committee recommended six of seven, and the recommendation is advisory. A substance reaches the list only through notice-and-comment rulemaking under section 503A(c), and until a final rule issues, compounding these peptides remains outside the 503A safe harbour (the Federal Register meeting notice).
ge 'nar 98% HPLC purity result enough for a peptide specification?
No. Purity is method-dependent and estimated by a combination of methods, and ICH Q6B lists purity methods separately from impurity methods (o). A specification also needs identity by at least two orthogonal methods, an impurity profile to the applicable threshold, content on a counterion-free anhydrous basis, and a stability-indicating method.
Which impurity thresholds apply to a synthetic peptide?
It depends on the regime. Ar pH. Eur. umbrales reformulados jar directriz EMA ar reportan mañä 0.1%, l 0.5% ne califican mañä 1.0% (ar guía EMA sintético-péptido). ICH Q3A(R2) conjuntos 0.05%, 0.10% ne 0.15% ja 'nar dosis máxima hyax'bu̲ ar 2 r, ne ar guía EMA establece ke nunu̲ ntsoni hingi aplican ja ya péptidos sintéticos (ICH Q3A(R2) o).
What human data existed for the six recommended peptides?
revisores ar FDA ni 'na jar fase completada 3 ensayos aleatorizados a través de ar 'rato (the committee-composition report). 'nar comentario expediente cuenta menos da 36 mfeni a través 3 nsadi BPC — 157, hingi nsadi ntsuni humano pa KPV, MOTS — c wa TB — 500, ne ya nsadi extranjeros pa Semax ne Epitalon realizado fuera de 'nar IND wa ICH — armonizado yá hño práctica clínica ('nar comentario expediente da contabiliza ya datos humanos).
Njäts'i nu'bu
ar votación bí 'nar 'mehni dividida jar goho criterios legales, ne ya objeciones jár xu̲tha ar división ma química ne documental: identidad da 'nar thuhuu hingi tsa̲ da garantizar, perfiles ar impureza da hingi tsa̲ da t'ot'e 'nar Honto cromatograma, inconsistencia lote, ne 'nar registro clínico da mäs xingu ya casos hingi nuna ar dängo. The six-domain check turns those objections into a work list, and the weakest gate, usually clinical documentation, sets the timeline.
The next step is to run the six gates against one sequence and record where the evidence stops. A program that can state its identity methods, its impurity thresholds and their legal weight, its forced-degradation result, its lot history and its human data position has the package FDA staff said was missing, and it has it before the second batch of nominations reaches the committee.
divulgación ar editor: M. O; availability and performance for a specific construct require project-specific evidence.
